Macdougall I C, Davies M E, Hutton R D, Coles G A, Williams J D
Institute of Nephrology, University of Wales College of Medicine, Royal Infirmary, Cardiff.
Br J Haematol. 1991 Apr;77(4):550-8. doi: 10.1111/j.1365-2141.1991.tb08625.x.
Whole blood, plasma, and serum viscosity together with red cell deformability were measured before and during treatment of renal anaemia with recombinant human erythropoietin (EPO). Whole blood viscosity (WBV) progressively increased during the first 4 months of treatment in association with the rise in haemoglobin concentration. When the WBV was corrected to a standard haemoglobin concentration no change in blood viscosity was observed, neither was there any alteration in a derived index of red cell deformability, or in the plasma and serum viscosities. In addition, a direct measurement of red cell deformability using a filtration technique before EPO therapy was similar to that obtained in 30 healthy volunteers. There was no significant change in this parameter over the first 9 months of treatment. The rheological changes which occur with correction of anaemia with EPO can be explained solely by the increase in circulating haemoglobin mass rather than to any change in the properties of the plasma or red cells themselves.
在用重组人促红细胞生成素(EPO)治疗肾性贫血之前及治疗期间,对全血、血浆和血清黏度以及红细胞变形性进行了测量。在治疗的前4个月中,全血黏度(WBV)随着血红蛋白浓度的升高而逐渐增加。当将WBV校正至标准血红蛋白浓度时,未观察到血液黏度的变化,红细胞变形性的衍生指数、血浆和血清黏度也均未改变。此外,在EPO治疗前使用过滤技术直接测量的红细胞变形性与30名健康志愿者所测得的相似。在治疗的前9个月中,该参数无显著变化。EPO纠正贫血时发生的流变学变化可仅由循环血红蛋白量的增加来解释,而非血浆或红细胞自身特性的任何改变。